CDKN1A and neoplasm: Several reports indicate that increased p21 expression is associated with tumor progression and a poor prognosis in prostate [32, 33], ovarian [34], cervical [35], breast [36] and esophageal squamous cell carcinomas [37], as well as in brain tumors [38].